查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2015192

核酸检测市场：全球市场按产品类型、技术、检体类型、应用和最终用户分類的预测——2026-2032年

Nucleic Acid Testing Market by Product Type, Technology, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年核酸检测市场价值为104.7亿美元，预计到2026年将成长至113.3亿美元，复合年增长率为9.50%，到2032年将达到197.7亿美元。

主要市场统计数据
基准年 2025 104.7亿美元
预计年份：2026年 113.3亿美元
预测年份 2032 197.7亿美元
复合年增长率 (%) 9.50%

简要说明技术、法规和资料管治的融合如何改变核酸检测在各领域的部署。

核酸检测已从一项小众的实验室应用发展成为一项涵盖临床诊断、生命科学研究和生物防御等领域的基础技术。近年来，检测化学、样品製备流程和数位讯号处理技术的进步显着提高了分析灵敏度和处理能力，并缩短了检测结果的获取时间。这种转变使得核酸检测的应用范围从集中式分子检查室扩展到照护现场（POC​​）、分散式临床试验和环境监测倡议。

模组化设备、人工智慧驱动的分析以及确保稳定供应的试剂策略如何推动去中心化分子诊断进入新时代。

核酸检测领域正经历着一场变革性的转变，这得益于仪器小型化、人工智慧分析和检测化学多样化的融合。小型化降低了去中心化的门槛，使得仪器能够处理少量检体并简化操作流程，从而适用于门诊和患者现场检测。同时，机器学习模型正被整合到讯号处理流程中，从而提高了准确性，减少了假阳性，并实现了自动化品管，即使在非专业环境下也能获得可靠的检测结果。

对关税政策变化如何影响整个分子检测供应链的製造在地化、筹资策略和采购韧性进行定性分析。

影响进口实验室设备、试剂和耗材的政策调整和关税措施对核酸检测的供应链设计和筹资策略有显着影响。关税上调会提高精密光学元件、 聚合酵素连锁反应热迴圈仪和特殊酵素等关键零件的到货成本，进而影响设备和试剂盒生产商的采购决策。为此，一些供应商正在加快关键生产流程的本地化，并对替代供应商进行认证，以降低跨境关税波动带来的风险。

策略性细分揭示了产品类型、技术模式、检体矩阵、应用案例和最终用户实际情况如何共同决定机会和优先事项。

对产品类型趋势的洞察揭示了仪器、试剂/试剂盒和软体/服务的不同需求驱动因素。仪器的部署与处理能力需求和部署环境密切相关，而试剂/试剂盒的需求则受检测稳健性、储存稳定性和供应连续性的影响。软体和服务正日益透过资料分析、法规支援和工作流程整合创造价值，从而实现除一次性耗材之外的持续收入。从技术角度来看，数位PCR和次世代定序在复杂应用中展现出高灵敏度和多重分析能力，而等温扩增和即时PCR因其快速且经济高效的诊断方法而仍然具有吸引力。微阵列平台在特定的基因组筛检和研究领域继续发挥至关重要的作用，其预先定义的探针组能够提供高效的标靶分析。

区域间在基础建设、法规结构和公共卫生优先事项上的差异，如何影响产品引进和市场进入策略的差异化？

区域趋势持续影响着核酸检测领域相关人员的产品策略和市场进入方式。美洲地区拥有先进的检查室基础设施和快速发展的临床网络，有利于高通量平台、整合IT系统和完善的监管流程。这种环境支持精准肿瘤检测和高通量传染病检查等复杂应用，同时也对资料安全和保险报销制度的合规性提出了更高的要求。

优先考虑竞争动态、可重复性、供应弹性和卓越服务，并透过平台创新、协作生态系统和整合策略来实现。

核酸检测产业的企业发展趋势呈现出平台创新、策略伙伴关係和垂直整合并存的特性。领先的仪器开发人员持续投资，致力于拓展检测产品线、提高检测通量并缩短检测时间；而试剂盒和试剂生产商则专注于配方稳定性和简化工作流程，以拓宽应用场景。软体和服务供应商的角色日益凸显，他们透过提供资料分析、品质保证和法规文件等服务，与以硬体为中心的产品和服务形成互补，并深化客户关係。

为领导企业提供可操作且有影响力的策略措施，以加速采用、增强供应链韧性并实现整合硬体和软体产品的获利。

领导企业应优先考虑以下几项切实可行的策略，以克服复杂性并实现永续成长。首先，投资于模组化平台架构，以实现快速添加检测项目并轻鬆检验所有检体类型。模组化设计可缩短产品开发前置作业时间，并能快速回应突发的公共卫生需求。其次，制定紧急时应对计画链应急计划，包括双供应商模式、关键部件的本地化生产方案以及策略性库存管理政策，以应对关税波动和物流中断。

采用多方面、交叉检验的研究途径，结合专家访谈、技术文献和监管趋势，确保整合可靠的知识和可行的建议。

本研究结合了对仪器製造、试剂开发、临床检查室和监管事务领域意见领袖的定性访谈，并辅以对同行评审文献、技术白皮书和政策指南的系统性二次分析。调查方法强调交叉验证，透过将相关人员的观点与已记录的产品规格和已发表的检验研究进行三角检验。访谈重点在于产品开发蓝图、监管策略、生产依赖性和顾客接受度挑战，使分析立足于实际情况。

一份权威的综合分析报告，强调了将技术卓越性、营运韧性和协作商业化相结合的必要性。

总之，核酸检测正处于一个转折点，技术进步、监管成熟和采购重点的转变正在重塑诊断技术的开发、检验和交付方式。模组化仪器、灵活的试剂策略和软体驱动的分析技术的相互作用，正在催生新的经营模式，这些模式强调互通性、所有检体类型均可重复的性能以及强大的售后服务能力。那些能够根据当地监管环境调整产品设计并投资于供应链柔软性的相关人员，将更有能力将技术能力转化为临床和商业性成果。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：核酸检测市场：依产品类型划分

  • 装置
  • 试剂和试剂盒
  • 软体服务

第九章：核酸检测市场：依技术划分

  • 数位PCR
  • 等温扩增
  • 微阵列
  • 次世代定序
  • 即时PCR

第十章：依检体类型分類的核酸检测市场

  • 血
  • 唾液
  • 棉花棒
  • 组织
  • 尿

第十一章：核酸检测市场：依应用领域划分

  • 临床诊断
  • 药物发现
  • 法医学
  • 研究
  • 兽医诊断

第十二章：核酸检测市场：依最终用户划分

  • 学术研究机构
  • 诊断检测实验室
  • 医院和诊所
  • 製药和生物技术公司

第十三章：核酸检测市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：核酸检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 核酸检测市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国核酸检测市场

第十七章：中国核酸检测市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Illumina, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Seegene Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-036C5CF3B554

The Nucleic Acid Testing Market was valued at USD 10.47 billion in 2025 and is projected to grow to USD 11.33 billion in 2026, with a CAGR of 9.50%, reaching USD 19.77 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.47 billion
Estimated Year [2026] USD 11.33 billion
Forecast Year [2032] USD 19.77 billion
CAGR (%) 9.50%

A concise primer on how technological, regulatory, and data governance convergences are reshaping nucleic acid testing adoption across sectors

Nucleic acid testing has evolved from a laboratory niche to a foundational technology across clinical diagnostics, life sciences research, and biodefense. Recent advances in assay chemistry, sample preparation workflows, and digital signal processing have increased analytical sensitivity and throughput while reducing time to result. This transformation has expanded the range of use cases beyond centralized molecular labs into point-of-care settings, decentralized clinical trials, and environmental surveillance initiatives.

As technologies have matured, regulatory bodies have increasingly harmonized validation expectations for molecular assays and platforms, enabling clearer pathways for clinical adoption. At the same time, developers are integrating software-driven analytics and cloud-enabled data management to enhance interpretability and compliance. Consequently, stakeholders must navigate a landscape where technological capability, regulatory alignment, and data governance converge to determine the pace at which new offerings reach patients, researchers, and public health programs.

Given these dynamics, strategic planners should focus on interoperability, assay robustness across diverse sample types, and scalable manufacturing of reagents and consumables. In parallel, investors and advisors are evaluating platform extensibility, downstream data services, and partnerships that bridge laboratory and clinical workflows. Transitioning from capability demonstrations to sustained clinical utility remains the central challenge and opportunity for organizations active in nucleic acid testing.

How modular instruments, AI-driven analytics, and supply-resilient reagent strategies are catalyzing a new era of decentralized molecular diagnostics

The nucleic acid testing landscape is undergoing transformative shifts driven by the convergence of miniaturized instrumentation, AI-enabled analytics, and expanded assay chemistries. Miniaturization has lowered barriers to decentralization, enabling devices that operate with reduced sample volumes and simplified workflows suitable for outpatient clinics and near-patient settings. Concurrently, machine learning models are being integrated into signal processing pipelines to improve accuracy, reduce false positives, and support automated quality control, thereby enabling higher-confidence results in non-specialist environments.

Platform modularity is another defining trend. Manufacturers are designing instruments with swappable assay modules and open software architectures to accommodate emergent pathogen targets and multiplexed testing needs. This design philosophy supports faster response to public health threats and more efficient product lifecycle management. Additionally, reagent manufacturers are focusing on lyophilized chemistries and room-temperature stable kits to address supply chain fragility and logistical constraints in varied geographies.

Finally, there is a rising emphasis on end-to-end solutions that integrate sample collection, cloud-based data management, and clinical decision support. These holistic offerings are elevating the role of software and services within the traditional diagnostics value chain, creating new recurring revenue opportunities while also raising data privacy and interoperability considerations that organizations must proactively address.

Qualitative analysis of how tariff policy shifts influence manufacturing localization, sourcing strategies, and procurement resilience across the molecular testing supply chain

Policy adjustments and tariff actions affecting imported laboratory equipment, reagents, and consumables have material implications for supply chain design and procurement strategies in nucleic acid testing. Increased tariffs raise the landed cost of key components such as precision optics, thermal cyclers, and specialty enzymes, which in turn influences the sourcing decisions of instrument makers and kit manufacturers. In response, some suppliers accelerate localization of critical manufacturing steps or qualify alternative suppliers to mitigate exposure to cross-border tariff volatility.

Tariff-driven cost pressures also incentivize product redesigns that reduce dependence on tariff-exposed inputs through component substitution, consolidation of supplier bases, or migration to standardized, locally sourced parts. These strategic shifts can improve resilience but may require upfront investments in revalidation and quality management to ensure assay performance remains uncompromised. For end users, procurement cycles are lengthening as organizations weigh total cost of ownership, service coverage, and supply continuity rather than relying solely on unit price.

Moreover, policy uncertainty encourages greater emphasis on contractual protections, dual-sourcing strategies, and inventory buffering for critical reagents. As a result, stakeholders who proactively assess tariff exposure and implement adaptive sourcing and manufacturing approaches enhance their market agility and reduce downstream operational disruptions in testing workflows.

Strategic segmentation reveals how product type, technology modality, sample matrices, application use cases, and end-user realities jointly define opportunity and prioritization

Insight into product type dynamics reveals distinct demand drivers for instruments, reagents and kits, and software and services. Instrument adoption is closely tied to throughput requirements and deployment setting, while reagents and kits are governed by assay robustness, storage stability, and supply continuity. Software and services increasingly capture value through data analytics, regulatory support, and workflow integration, enabling recurring revenue beyond single-use consumables. When examined by technology, digital PCR and next generation sequencing offer high sensitivity and multiplexing capabilities for complex applications, while isothermal amplification and real-time PCR remain attractive for rapid, cost-effective diagnostics. Microarray platforms retain relevance in certain genomic screening and research contexts where predefined probe panels provide efficient target analysis.

Sample type considerations shape assay design and user experience across blood, saliva, swabs, tissue, and urine. Blood-based assays typically prioritize analytical sensitivity and standardized collection, whereas saliva and swab-based approaches emphasize ease of collection and stability. Tissue and urine assays open specialized diagnostic windows that require tailored extraction and matrix-specific validation. Application areas such as clinical diagnostics, drug discovery, forensics, research, and veterinary diagnostics each impose unique regulatory, throughput, and data-interpretation requirements that influence product roadmaps. End-user segments including academic research institutes, diagnostic laboratories, hospitals and clinics, and pharmaceutical and biotechnology companies differ in purchasing cadence, emphasis on regulatory compliance, and openness to integrated software-driven solutions.

Taken together, these segmentation lenses demonstrate that success in nucleic acid testing depends on aligning product development with the intersection of technological capability, sample-preparation constraints, and the operational realities of distinct end users. Product teams should therefore prioritize modular platforms, validated workflows for diverse sample matrices, and flexible commercial models that reflect the needs of both research-focused and clinical-facing customers.

How distinct regional infrastructure, regulatory frameworks, and public health priorities are shaping differentiated strategies for product adoption and market access

Regional dynamics continue to influence product strategies and go-to-market approaches for nucleic acid testing stakeholders. The Americas feature advanced laboratory infrastructure and fast-adopting clinical networks that favor high-throughput platforms, integrated IT systems, and comprehensive regulatory pathways. This environment supports complex applications such as precision oncology assays and high-volume infectious disease testing, while also demanding stringent data security and reimbursement alignment.

Europe, the Middle East and Africa present a more heterogeneous landscape, where pockets of regulatory harmonization coexist with varying levels of laboratory infrastructure. In many EMEA markets, buyers value robust supply chains, reagent stability, and solutions that can be validated across multiple regulatory jurisdictions. Partnerships with local distributors and investments in training and service logistics help overcome fragmentation and accelerate adoption in both clinical and veterinary settings.

Asia-Pacific displays rapid adoption of point-of-care and decentralized testing solutions driven by public health priorities, investments in local manufacturing, and large-scale research initiatives. Diverse healthcare delivery models across the region require adaptable product configurations, multilingual software interfaces, and flexible financing arrangements. Across all regions, interoperability, supply resilience, and alignment with local regulatory expectations remain essential considerations for sustained market access and commercial success.

Competitive dynamics driven by platform innovation, collaborative ecosystems, and integration strategies that prioritize reproducibility, supply resilience, and service excellence

Company behavior in the nucleic acid testing domain is characterized by a mix of platform innovation, strategic partnerships, and vertical integration. Leading instrument developers continue to invest in expanding assay menus, improving throughput, and shortening time to result, while kit and reagent producers focus on formulation stability and simplified workflows to broaden use cases. Software and services providers are increasingly critical, offering data analytics, quality assurance, and regulatory documentation that augment hardware-centric offerings and deepen customer relationships.

Collaborative models are prominent, with diagnostic developers partnering with academic centers, contract manufacturers, and software integrators to accelerate validation and scale production. These alliances help spread risk and reduce time to market for complex assays, particularly when navigating multi-jurisdictional regulatory environments. At the same time, some players pursue backward integration to secure critical reagent supplies or forward integration to offer bundled testing solutions that include sample collection, analytics, and reporting.

Competitive differentiation increasingly rests on service excellence, regulatory expertise, and the ability to deliver reproducible performance across diverse sample types and laboratory settings. Organizations that combine robust technical performance with dependable global supply chains and proactive customer support are best positioned to capture adoption across clinical, research, and applied diagnostic segments.

Practical, high-impact strategic moves for leaders to accelerate adoption, fortify supply chain resilience, and monetize integrated hardware-software offerings

Leaders in nucleic acid testing should prioritize several actionable strategies to navigate complexity and unlock sustained growth. First, invest in modular platform architectures that enable rapid assay additions and ease of validation across sample types. Modular designs reduce product development timelines and allow quicker responses to emergent public health needs. Second, develop supply chain contingency plans that include dual sourcing, local manufacturing options for critical components, and strategic inventory policies to buffer against tariff volatility and logistic disruptions.

Third, enhance value propositions by pairing hardware with cloud-enabled analytics, regulatory support services, and training programs that reduce friction in customer adoption. Such integrated offerings increase stickiness and create recurring revenue streams. Fourth, pursue targeted partnerships with academic, clinical, and manufacturing organizations to share validation burden and accelerate market entry in fragmented regulatory jurisdictions. Finally, embed privacy-by-design and interoperability standards into software roadmaps to meet growing expectations around data governance and clinical integration.

By executing on these priorities, organizations can balance innovation speed with the operational rigor required for clinical adoption, thereby converting technical capability into lasting market relevance.

A multi-source, triangulated research approach combining expert interviews, technical literature, and regulatory signals to ensure robust insight synthesis and actionable recommendations

This research synthesizes primary qualitative interviews with thought leaders across instrument manufacturing, reagent development, clinical laboratories, and regulatory affairs, complemented by systematic secondary analysis of peer-reviewed literature, technical white papers, and policy guidance. The methodology emphasizes cross-validation of insights by triangulating stakeholder perspectives with documented product specifications and published validation studies. Interviews focused on product development roadmaps, regulatory strategies, manufacturing dependencies, and customer adoption challenges to ground analysis in operational realities.

Secondary sources included reagent and platform technical notes, clinical validation reports, and public regulatory communications to ensure that conclusions reflect verifiable performance characteristics and compliance expectations. The analytical framework structured findings across technology modality, sample matrix, application area, and end-user profile, enabling targeted recommendations that map to distinct strategic decisions. Finally, an iterative review process involving subject-matter experts ensured interpretive rigor and reduced the risk of bias, while supplemental sensitivity checks examined alternative scenarios for supply chain and regulatory developments.

A conclusive synthesis that emphasizes the necessity of marrying technical excellence with operational resilience and collaborative commercialization to achieve durable impact

In conclusion, nucleic acid testing sits at an inflection point where technical advances, regulatory maturation, and evolving procurement priorities are reshaping how diagnostics are developed, validated, and delivered. The interplay between modular instrumentation, resilient reagent strategies, and software-enabled analytics is creating new commercial models that reward interoperability, reproducible performance across sample types, and strong post-sale service capabilities. Stakeholders that align product design with regional regulatory realities and invest in supply chain flexibility will be best positioned to translate technical capability into clinical and commercial impact.

Moving forward, organizations should treat data governance, assay robustness, and customer enablement as core elements of product value rather than adjunct considerations. In doing so, they will not only enhance adoption rates but also build the institutional trust necessary for long-term integration into clinical workflows and public health infrastructures. Ultimately, the most successful players will be those who combine scientific excellence with pragmatic operational planning and collaborative go-to-market execution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nucleic Acid Testing Market, by Product Type

  • 8.1. Instruments
  • 8.2. Reagents & Kits
  • 8.3. Software & Services

9. Nucleic Acid Testing Market, by Technology

  • 9.1. Digital PCR
  • 9.2. Isothermal Amplification
  • 9.3. Microarray
  • 9.4. Next Generation Sequencing
  • 9.5. Real Time PCR

10. Nucleic Acid Testing Market, by Sample Type

  • 10.1. Blood
  • 10.2. Saliva
  • 10.3. Swabs
  • 10.4. Tissue
  • 10.5. Urine

11. Nucleic Acid Testing Market, by Application

  • 11.1. Clinical Diagnostics
  • 11.2. Drug Discovery
  • 11.3. Forensics
  • 11.4. Research
  • 11.5. Veterinary Diagnostics

12. Nucleic Acid Testing Market, by End User

  • 12.1. Academic Research Institutes
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals & Clinics
  • 12.4. Pharmaceutical & Biotechnology Companies

13. Nucleic Acid Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Nucleic Acid Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Nucleic Acid Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Nucleic Acid Testing Market

17. China Nucleic Acid Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Agilent Technologies, Inc.
  • 18.7. Becton, Dickinson and Company
  • 18.8. Bio-Rad Laboratories, Inc.
  • 18.9. bioMerieux SA
  • 18.10. Danaher Corporation
  • 18.11. F. Hoffmann-La Roche Ltd.
  • 18.12. Hologic, Inc.
  • 18.13. Illumina, Inc.
  • 18.14. PerkinElmer, Inc.
  • 18.15. QIAGEN N.V.
  • 18.16. Quest Diagnostics Incorporated
  • 18.17. Seegene Inc.
  • 18.18. Siemens Healthineers AG
  • 18.19. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEIC ACID TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEIC ACID TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY FORENSICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY FORENSICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY FORENSICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY VETERINARY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY VETERINARY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY VETERINARY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. GCC NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GCC NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. GCC NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. GCC NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. GCC NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. GCC NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. G7 NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. G7 NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. G7 NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. G7 NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. G7 NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. G7 NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. NATO NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. NATO NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NATO NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. NATO NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)